EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 March 2018
EMA/809462/2017
EMEA/H/C/000966

Public statement

IDflu

Withdrawal of the marketing authorisation in the European Union

On 19 March 2018, the European Commission withdrew the marketing authorisation for IDflu (influenza vaccine (split virion, inactivated)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Pasteur SA, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

IDflu was granted marketing authorisation in the EU on 24 February 2009 for prophylaxis of influenza in individuals 18 years of age and over. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. The product had not been marketed in the EU since 2015.

IDflu was a duplicate application to Intanza, which is authorised in the EU to prevent influenza in individuals 60 years of age and over, especially in those who are at increased risk of associated complications. IDflu is an identical product to Vaxigrip and is similar to VaxigripTetra, which are marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for these vaccines.

The European Public Assessment Report (EPAR) for IDflu will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact